SolasCure completes Phase II clinical trial, demonstrating accelerated healing with Aurase Wound Gel
SOLASCURE Ltd (SolasCure), a biotechnology company developing a novel treatment to transform chronic wound healing, today announced the successful completion of its second Phase II clinical trial, ...
XProâ„¢ is a next-generation, selective soluble TNF inhibitor designed to selectively neutralize soluble TNF (sTNF) and restore ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results